Literature DB >> 12215390

An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood.

N Grebenchtchikov1, C G J Sweep, A Geurts-Moespot, A Piffanelli, J A Foekens, Th J Benraad.   

Abstract

Endogenous heterophilic antibodies in blood are known to interfere with two-site enzyme-linked immunosorbent assays (ELISAs) evoking false positive signals. In the present study, we describe an assay for the assessment of components of the plasminogen activation system (uPA, tPA and PAI-1, and their complexes) in blood which is not susceptible to interference by heterophilic antibodies. In the ELISA format, two avian (duck, chicken) antibodies are employed in the pre-analyte and two mammalian (rabbit, goat) antibodies in the post-analyte stage. The assay is compared to our earlier reported ELISA for measuring uPA, tPA and PAI-1 components in tumor tissue extracts. Applying the so-called "nonsense formats", designed against non-existent components, to the NIBSC reference preparation of rheumatoid factor (RF), no response was found with the new assay, whereas a clear RF dose-dependent interfering signal was observed with the original assay designed for tumor tissue extracts. Analysis of tumor-tissue based international reference preparations (RBG EORTC 101094 and 040297), human anti-mouse antibodies (HAMA) containing sera, and sera from patients with rheumatoid arthritis (RA), also displayed no false positive signals. In conclusion, we have developed an ELISA that permits the determination of blood levels of components in the urokinase system, free from disturbance by endogenous heterophilic antibodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215390     DOI: 10.1016/s0022-1759(02)00213-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.

Authors:  S F Mulder; M J Boers-Sonderen; H F M van der Heijden; K C P Vissers; C J A Punt; C M L van Herpen
Journal:  Target Oncol       Date:  2014-01-21       Impact factor: 4.493

2.  IL-8 and cathepsin B as melanoma serum biomarkers.

Authors:  Hongtao Zhang; Ting Fu; Suzanne McGettigan; Suresh Kumar; Shujing Liu; David Speicher; Lynn Schuchter; Xiaowei Xu
Journal:  Int J Mol Sci       Date:  2011-02-25       Impact factor: 5.923

Review 3.  The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory Diagnosis.

Authors:  Yu Fu; Yunbao Pan; Zhiqiang Li; Yirong Li
Journal:  Front Microbiol       Date:  2021-01-13       Impact factor: 5.640

4.  Expression and function of macrophage migration inhibitory factor (MIF) in melioidosis.

Authors:  W Joost Wiersinga; Thierry Calandra; Liesbeth M Kager; Gerritje J W van der Windt; Thierry Roger; Didier le Roy; Sandrine Florquin; Sharon J Peacock; Fred C G J Sweep; Tom van der Poll
Journal:  PLoS Negl Trop Dis       Date:  2010-02-16

5.  Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA.

Authors:  E McKiernan; K O'Brien; N Grebenchtchikov; A Geurts-Moespot; A M Sieuwerts; J W M Martens; V Magdolen; D Evoy; E McDermott; J Crown; F C G J Sweep; M J Duffy
Journal:  Br J Cancer       Date:  2008-10-28       Impact factor: 7.640

6.  Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.

Authors:  Sasja F Mulder; Dirk Bertens; Ingrid M E Desar; Kris C P Vissers; Peter F A Mulders; Cornelis J A Punt; Dick-Johan van Spronsen; Johan F Langenhuijsen; Roy P C Kessels; Carla M L van Herpen
Journal:  BMC Cancer       Date:  2014-03-24       Impact factor: 4.430

7.  Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes.

Authors:  Yanyun Wang; Haibo Luo; Guanglu Che; Yanqin Li; Jun Gao; Qiongli Yang; Bin Zhou; Linbo Gao; Tao Wang; Yujie Liang; Lin Zhang
Journal:  Mol Med Rep       Date:  2018-05-03       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.